dostarlimab – Talk Bio

GSK and AnaptysBio Enter Legal Dispute Over Jemperli License Amid Allegations of Contract Breaches

3 weeks ago talkbio0Tagged AnaptysBio, dostarlimab, Jemperli, License Agreement, Litigation, Malignant neoplasm of endometrium, Neoplasms, royalties, SmithKline Beecham, TESARO

GSK; AnaptysBio; Jemperli; dostarlimab; TESARO; litigation; license agreement; oncology; royalties; endometrial cancer

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

7 months ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

GSK Secures Broad Label Expansion for Jemperli in First-Line Endometrial Cancer

1 year ago talkbio0Tagged Approved, dostarlimab, immuno-oncology, Jemperli, Keytruda, Malignant neoplasm of endometrium, Pharmacotherapy, SmithKline Beecham, United States Food and Drug Administration

GSK, Jemperli, dostarlimab, endometrial cancer, FDA approval, chemotherapy, immuno-oncology, Keytruda, Merck